Metabolic syndrome and endometrial cancer-PPARγ ligands as useful drug candidates for endocrine treatment-

点击翻译按钮获取中文摘要

The inspection from the viewpoint of metabolic syndrome is useful for the sorting of the endometrial cancer risk. In addition, PPARγ ligands, known as the metabolic syndrome therapeutic drugs, and the agonists of retinoid receptors forming heterodimerization with PPAR, should be important drug candidates for endocrine treatment of endometrial cancer. On the other hand, we indicated aromatase played a very important role in the local biosynthesis of estrogen in human endometrial cancer through tumor-stromal cell interactions. Therefore, aromatase inhibitors should be useful drugs especially for patients with endometrial cancers, which have aromatase activities.